{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:01:42Z","timestamp":1789524102073,"version":"build-2803163510"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Levofloxacin, the L-isomer of the racemic fluoroquinolone ofloxacin, is a broad-spectrum antibiotic with broad clinical applications in both prophylactic and therapeutic indications. However, it has been associated with various adverse reactions, including Guillain\u2212Barr\u00e9 syndrome (GBS). GBS is an immune-mediated peripheral neuropathy that typically presents with acute-onset symmetrical flaccid paralysis. Here, we report a case of GBS temporally associated with levofloxacin exposure that improved after initiation of efgartigimod, following limited response to plasma exchange, methylprednisolone, and intravenous immunoglobulin. To our knowledge, there are no previously published cases of GBS associated with levofloxacin exposure treated with efgartigimod therapy. This case suggests that efgartigimod may represent a promising treatment option for GBS temporally associated with levofloxacin exposure. However, this single case cannot establish efficacy, and delayed responses to prior therapies or spontaneous recovery remain possible alternative explanations. Further studies with larger cohorts are needed to clarify the mechanisms underlying this therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1729694","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:53:16Z","timestamp":1767768796000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case Report: Guillain\u2212Barr\u00e9 syndrome temporally associated with levofloxacin exposure and improvement following efgartigimod treatment"],"prefix":"10.3389","volume":"16","author":[{"given":"Shiyuan","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lining","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxia","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12872-023-03261-4","article-title":"Guillain-Barre syndrome after myocardial infarction: a case report and literature review","volume":"23","author":"Wen","year":"2023","journal-title":"BMC Cardiovasc Disord"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200932040-00005","article-title":"Vaccines and guillain-barr\u00e9 Syndrome","volume":"32","author":"Haber","year":"2009","journal-title":"Drug Saf"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain-Barr\u00e9 syndrome: pathogenesis, diagnosis, treatment and prognosis","volume":"10","author":"van den Berg","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.792805","article-title":"Levofloxacin for the treatment of pyelonephritis","volume":"14","author":"Rafat","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2013.12.009","article-title":"Peripheral neuropathy and Guillain-Barr\u00e9 syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis","volume":"24","author":"Ayad","year":"2014","journal-title":"Ann Epidemiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02101-9","article-title":"Efgartigimod: A review in generalised myasthenia gravis","volume":"84","author":"Blair","year":"2024","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e40700","DOI":"10.1097\/md.0000000000040700","article-title":"Resolution of acute motor axonal neuropathy in a patient after treatment with efgartigimod: A case report","volume":"103","author":"Zhou","year":"2024","journal-title":"Med (Baltimore)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12321-4","article-title":"Efgartigimod in the treatment of Guillain-Barr\u00e9 syndrome","volume":"271","author":"Zhang","year":"2024","journal-title":"J Neurol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e70308","DOI":"10.1111\/ene.70308","article-title":"Efgartigimod as add-on treatment in refractory guillain-barr5 syndrome: A case report","volume":"32","author":"Ripellino","year":"2025","journal-title":"Eur J Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251314746","article-title":"Sequential administration of efgartigimod shortened the course of Guillain-Barr\u00e9 syndrome: a case series","volume":"18","author":"Chen","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/bf01691582","article-title":"Safety of trovafloxacin in treatment of lower respiratory tract infections","volume":"17","author":"Williams","year":"1998","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg209","article-title":"Adverse drug reactions: implications for the development of fluoroquinolones","volume":"51","author":"Ball","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Z429","article-title":"Peripheral neuropathy associated with fluoroquinolones","volume":"35","author":"Cohen","year":"2001","journal-title":"Ann Pharmacother"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00517-1","article-title":"Guillain-barr\u00e9 syndrome","volume":"397","author":"Shahrizaila","year":"2021","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09742-2","article-title":"Axonal variants of Guillain-Barr\u00e9 syndrome: an update","volume":"268","author":"Shang","year":"2021","journal-title":"J Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-barre syndrome following vaccination in the national influenza immunization program, United States, 1976-19771","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/bf00874121","article-title":"Guillain-Barr syndrome during treatment with ofloxacin","volume":"240","author":"Schmidt","year":"1993","journal-title":"J Neurol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C525","article-title":"Levofloxacin-induced autoimmune hemolytic anemia","volume":"37","author":"Oh","year":"2003","journal-title":"Ann Pharmacother"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e85483","DOI":"10.7759\/cureus.85483","article-title":"Ciprofloxacin-induced erythema multiforme major unmasking systemic lupus erythematosus","volume":"17","author":"Alicea","year":"2025","journal-title":"Cureus"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2021.17.2.273","article-title":"Determining the utility of the guillain-barr\u00e9 Syndrome classification criteria","volume":"17","author":"Tan","year":"2021","journal-title":"J Clin Neurol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-020-0616-8","article-title":"Newer immunotherapies for the treatment of acute neuromuscular disease in the critical care unit","volume":"22","author":"Patel","year":"2020","journal-title":"Curr Treat Options Neurol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5603\/ait.2013.0002","article-title":"Complications in patients treated with plasmapheresis in the intensive care unit","volume":"45","author":"Szczeklik","year":"2013","journal-title":"Anaesthesiol Intensive Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/mus.21433","article-title":"Consensus statement: The use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee","volume":"40","author":"Donofrio","year":"2009","journal-title":"Muscle Nerve"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/cnd.0000000000000235","article-title":"Immunoglobulin treatment in neuromuscular medicine","volume":"20","author":"Burakgazi","year":"2019","journal-title":"J Clin Neuromuscul Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1172\/jci97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2025.578712","article-title":"Efficacy of FcRn antagonist efgartigimod in the treatment of Miller-Fisher\/Guillain-Barr\u00e9 overlap syndrome: Two case reports","volume":"407","author":"Fan","year":"2025","journal-title":"J Neuroimmunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.5811\/cpcem.2020.7.48507","article-title":"Miller-fisher syndrome: A case report and review of the literature","volume":"4","author":"Truong","year":"2020","journal-title":"Clin Pract cases Emerg Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1729694\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:53:35Z","timestamp":1767768815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1729694\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2025.1729694"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1729694","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"article-number":"1729694"}}